|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Though no biallelic loss of BLM was no noted in cancers, a surprising number of the BLM germline heterozygotes had pathogenic BRCA2 mutations in their tumor.
|
31816118 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Whether BLM-s expression correlates with any subtype of human tumors has not been investigated.
|
30261190 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high expression of BLM (Bloom syndrome) helicase in tumors involves its strong association with cell expansion.
|
31660888 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BLM dysfunction has been implicated in tumor development, most recently during PC tumorigenesis.
|
31210839 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, BLM carries out its function as a tumor suppressor by enhancing c-Jun turnover and thereby preventing its activity as a proto-oncogene.
|
30044990 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite its putative tumor suppressor function, the contribution of BLM to human sporadic colorectal cancer (CRC) remains poorly understood.
|
27169843 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using targeted DNA sequencing, we analyzed the mutation profiles of the genes PKMYT1, AHCY, and BLM in tumor samples of five patients with MYCN amplified and 15 MYCN non-amplified NB.
|
27876123 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BLM and CHEK2 are two evolutionarily conserved genes that are somatically altered in a number of tumor types.
|
26318585 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Losses of heterozygosity affecting the wild-type allele were detected in none of the tumors from BLM mutation carriers, 3/18 (17 %) CHEK2-associated BC and 1/4 (25 %) NBN/NBS1-driven tumors.
|
24415413 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We showed an association between the A/A genotype (OR 2.45) and the A/C genotype (OR 0.41) of the g.96267 A>C-BLM polymorphism and G3 grade of tumor.
|
23404160 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hence, partly owing to its regulation of c-Myc stability, BLM acts as a 'caretaker tumor suppressor'.
|
23750012 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Defects in the human BLM gene cause Bloom syndrome, notable for early development of tumors in a broad variety of tissues.
|
23110454 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results provide a strong rationale for further developing WRN and BLM as biomarkers of tumor chemotherapeutic responsiveness.
|
20663905 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, both large scale and small scale genetic alterations are elevated when BLM is reduced, which may contribute to loss of function of tumor suppressor genes and subsequent tumorigenesis.
|
20299287 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Bloom syndrome is a genetic disorder associated with chromosomal instability and a predisposition to tumors that is caused by germline mutations of the BLM gene, a RecQ helicase.
|
18401830 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The BLM(Ash) mutation was carried by 0.80% of individuals with colorectal neoplasia, 0.87% of those with any type of cancer and 0.85% of controls.
|
12702560 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show that mice heterozygous for a targeted null mutation of Blm, the murine homolog of BLM, develop lymphoma earlier than wild-type littermates in response to challenge with murine leukemia virus and develop twice the number of intestinal tumors when crossed with mice carrying a mutation in the Apc tumor suppressor.
|
12242442 |
2002 |